The scientific record required to support the approval of a new molecular entity, or in Canada a new active substance, typically amounts to hundreds of thousands of pages of densely written scientific reports. In vitro studies explore the mechanism of action. The chemical stability, human metabolization, and consistent manufacture of a new molecule require careful evaluation. Beneficial effects, high doses, and long-term exposure are examined in animal models that may or may not predict effects in humans. Hundreds to thousands of patients are exposed in preapproval clinical testing. Although many new drugs are intended for long-term use, the international standard requires that only a few hundred patients be exposed to these drugs for 12 months or more. 5 Regulatory agency reviewers are faced with a formidable mass of scientific data that contain only modest amounts of information from direct patient testing. Therefore, important clinical questions may remain unanswered. There are increasing demands by legislatures, industry, medical professionals, and patients to make these difficult decisions even more quickly in both Canada and the United States.
The current FDA "Expedited Drug Development Pathway" now includes provisions to reduce the number and size of clinical trials, to accept more limited evidence of efficacy, and to initiate drug review before the completion of testing. It also sets short review deadlines. In fiscal year 2011, a total of 16 of 35 new molecular entities (46%) received a priority review from the FDA, 13 (37%) received additional fast-track treatment, and 24 (69%) were approved in the United States earlier than in Europe or Canada. 6 Getting faster access to newly developed, less thoroughly tested drugs is at best a mixed blessing. For the first 3 years after approval, new drugs should carry a special warning akin to the black triangle used in Britain. It should be prominent and mean to every physician, "New Drug: Caution Indicated." 
D
epression following an acute coronary syndrome (ACS) affects 2 in 5 patients and is one of the most important psychosocial predictors of a poor cardiovascular prognosis. 1 In the Coronary Psychosocial Evaluation Studies (COPES) randomized controlled trial, we compared the effectiveness of enhanced depression care, which comprised patient preference for problem-solving psychotherapy, antidepressant use, or both, through the use of a stepped-care algorithm, with usual care in patients with ACS and persistent depressive symptoms 3 months after discharge. 2 The 6-month trial demonstrated that enhanced depression care improved patient satisfaction with treatment and reduced depressive symptoms. However, the intervention's impact on health-related quality of life, health care utilization, and cost-effectiveness has not been evaluated. To help bridge this gap and inform decision making, we undertook a cost-effectiveness analysis of enhanced depression treatment in patients with ACS and persistent depressive symptoms using results from the COPES trial.
Methods. Data. We interviewed patients to determine their antidepressant and anxiolytic medication use and dose; ambulatory care visits with mental health specialists, cardiologists, and primary care physicians; and hospitalizations for stable angina, unstable angina, ST-segment elevation or non-ST-segment elevation myocardial infarction, and congestive heart failure. Hospitalizations were confirmed by medical chart review and adjudicated by 2 board-certified cardiologists. Hospital electronic health records were also actively surveyed for hospitalizations. Costs were estimated using average wholesale drug prices and Medicare reimbursement rates. Standardized measures of quality of life were obtained using the 12-Item Short Form Health Survey (SF-12) and converted to health utilities using the Short Form 6 Dimensions (SF-6D) scoring algorithm. 3 Statistical and Cost Analysis. Quality of life, health care utilization, and cost outcomes were adjusted for potential confounding by age, sex, ethnicity, race, marital status, education, depressive symptom severity, type of ACS, and left ventricular ejection fraction using linear regression models. To determine costeffectiveness, mean incremental costs and mean incremental quality-adjusted life-years were estimated using 6-month outcomes. We performed nonparamet-ric bootstrapping with 1000 random samples to estimate 95% confidence intervals for cost-effectiveness ratios. 4 Results. Quality-of-Life Outcomes. The mean (SD) age of the study population was 60 (10.6) years, and 53% were female, 49% were Hispanic, and 19% were African American. At the 6-month follow-up, greater improvements in health utility were observed in the intervention group compared with the usual care group, although were not statistically significant (0.60 vs 0.56; P= .07).
Use of Ambulatory Care. Among patients randomized to receive enhanced depression care, 51% reported using antidepressants or anxiolytics compared with 30% of patients receiving usual care, with mean costs of $261 compared with $236 (adjusted difference, $18; P = .81) (Table) . Use of mental health care was also more frequent in the intervention arm, with 75% visiting a mental health specialist at least once, compared with 35% in usual care arm (mean cost $585 vs $58; adjusted difference, $535; PϽ .001). The frequency of visits to cardiologists and primary care physicians was similar in the intervention and control groups, with 88% and 92% of patients reporting at least 1 cardiology appointment and 95% and 92% of patients reporting at least 1 primary care appointment, respectively. Mean total costs for ambulatory care in the intervention group were $1083 compared with $554 in the usual care group (adjusted difference, $536; P Ͻ.001).
Use of Hospital Care. The higher costs of mental health care and higher use of psychotropic medications in the intervention group were offset by savings in hospitalizations for major adverse cardiac events and heart failure. Overall, 5% of patients receiving enhanced depression care compared with 16% of patients receiving usual care were hospitalized for stable angina, unstable angina, STsegment elevation or non-ST-segment elevation myocardial infarction, or heart failure. This difference in hospitalization rates resulted in a cost difference of −$1782 (95% CI, −$3163 to −$402; P = .01).
Cost-effectiveness. Mean total health care costs, including costs for psychotropic medications, ambulatory care, and hospitalizations, totaled $1857 for the enhanced depression care group and $2797 for the usual care group (adjusted difference, −$1229 per patient; 95% CI, −$2652 to $195; P = .09). Because the intervention was cost saving on average, no mean cost-effectiveness ratio exists. Bootstrap analysis demonstrated that if society is willing to pay $30 000 per quality-adjusted life-year gained by enhanced depression care, the probability that this treatment approach will be considered cost-effective is 98%.
Comment. To our knowledge, this analysis is the first economic evaluation of enhanced depression treatment in patients with ACS and persistent depressive symptoms. A growing body of evidence suggests that mental health problems complicate physical health conditions and that this relationship worsens clinical outcomes, 1 increases hospitalizations, 5 and adversely affects quality of life. 6, 7 Another recent study of patients with depression and poorly controlled diabetes mellitus or coronary heart disease found that a multicomponent treatment program, with particular emphasis on depressive symptoms, reduced health care costs. 8 The findings from our study support this conclusion, while highlighting the need for larger studies with longer follow-up to examine the robustness and durability of these findings. 
